Advertisement

Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation

  • Kevin Dsouza
  • Cameron Pywell
  • Victor J. ThannickalEmail author
Reference work entry

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic modality for a number of malignant and nonmalignant conditions. Pulmonary complications following HSCT are associated with increased mortality and morbidity. These complications may be classified into infectious versus noninfectious, and early versus late based on the time of occurrence post-transplant. Thus, exclusion of infectious etiologies is the first step in the diagnoses of pulmonary complications. Late onset noninfectious pulmonary complications typically occur 3 months post-transplant. Bronchiolitis obliterans is the major contributor to late-onset pulmonary complications, and its clinical presentation, pathogenesis, and current therapeutic approaches are discussed. Idiopathic pneumonia syndrome is another important complication which usually occurs early, although its onset may be delayed. Organizing pneumonia is important to recognize due to its responsiveness to corticosteroids. Other late onset noninfectious pulmonary complications discussed here include pulmonary venoocclusive disease, pulmonary cytolytic thrombi, pleuroparenchymal fibroelastosis, thoracic air leak syndrome, and posttransplant lymphoproliferative disorders.

Keywords

Bronchiolitis obliterans Hematopoietic stem cell transplant Pulmonary complications Organizing pneumonia 

References

  1. 1.
    Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006;27(3):297–309.  https://doi.org/10.1055/s-2006-945530.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Alasaly K, Muller N, Ostrow DN, Champion P, FitzGerald JM. Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore). 1995;74(4):201–11.CrossRefGoogle Scholar
  3. 3.
    Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–83.  https://doi.org/10.1007/s11899-013-0162-5.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–8.  https://doi.org/10.1016/j.bbmt.2010.11.018.CrossRefPubMedGoogle Scholar
  5. 5.
    Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370(19): 1820–8.  https://doi.org/10.1056/NEJMra1204664.CrossRefPubMedGoogle Scholar
  6. 6.
    Bergeron A. Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Clin Chest Med. 2017;38(2):249–62.  https://doi.org/10.1016/j.ccm.2016.12.013.CrossRefPubMedGoogle Scholar
  7. 7.
    Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, Dominique S, de Revel T, Juvin K, Maillard N, Reman O, Contentin N, Robin M, Buzyn A, Socie G, Tazi A. Budesonide/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191(11):1242–9.  https://doi.org/10.1164/rccm.201410-1818OC.CrossRefPubMedGoogle Scholar
  8. 8.
    Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socie G, ALLOZITHRO Study Investigators. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA. 2017;318(6):557–66.  https://doi.org/10.1001/jama.2017.9938.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Riviere F, Robin M, Mani J, Lorillon G, Socie G, Tazi A. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018;51(5).  https://doi.org/10.1183/13993003.02617-2017.
  10. 10.
    Brownback KR, Thomas LA, McGuirk JP, Ganguly S, Streiler C, Abhyankar S. Effect of rituximab on pulmonary function in bronchiolitis obliterans syndrome due to graft-versus-host-disease. Lung. 2017;195(6): 781–8.  https://doi.org/10.1007/s00408-017-0051-0.CrossRefPubMedGoogle Scholar
  11. 11.
    Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant. 2008;41(8):677–86.  https://doi.org/10.1038/sj.bmt.1705990.CrossRefPubMedGoogle Scholar
  12. 12.
    Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82(1):45–52.  https://doi.org/10.1002/ajh.20752.CrossRefPubMedGoogle Scholar
  13. 13.
    Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Crothers K, Pusic I, Lee SJ, Williams KM. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13(11):1932–9.  https://doi.org/10.1513/AnnalsATS.201604-262OC.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med. 1989;111(5):368–76.CrossRefGoogle Scholar
  15. 15.
    Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230–9.CrossRefGoogle Scholar
  16. 16.
    Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, Brewer JP, Ferrara JL. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 2000;70(2):272–9.CrossRefGoogle Scholar
  17. 17.
    Cordier JF. Organising pneumonia. Thorax. 2000;55(4):318–28.CrossRefGoogle Scholar
  18. 18.
    Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28(2):422–46.  https://doi.org/10.1183/09031936.06.00013505.CrossRefGoogle Scholar
  19. 19.
    Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, Johnson G, Ward C. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015;70(5):442–50.  https://doi.org/10.1136/thoraxjnl-2014-205998.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis. 1993;147(6 Pt 1):1393–400.  https://doi.org/10.1164/ajrccm/147.6_Pt_1.1393.CrossRefPubMedGoogle Scholar
  21. 21.
    Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–16.PubMedGoogle Scholar
  22. 22.
    Dirou S, Malard F, Chambellan A, Chevallier P, Germaud P, Guillaume T, Delaunay J, Moreau P, Delasalle B, Lemarchand P, Mohty M. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. Bone Marrow Transplant. 2014;49(5):622–7.  https://doi.org/10.1038/bmt.2014.15.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C, Beelen DW. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 2007;92(4): 558–61.CrossRefGoogle Scholar
  24. 24.
    Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transplant. 2013;48(9):1224–9.  https://doi.org/10.1038/bmt.2013.17.CrossRefPubMedGoogle Scholar
  25. 25.
    Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood. 2017;129(18):2570–80.  https://doi.org/10.1182/blood-2017-01-758854.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10): 657–66.  https://doi.org/10.1016/S1083.CrossRefPubMedGoogle Scholar
  27. 27.
    Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinbi HT. Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol. 2003;28(3):373–8.  https://doi.org/10.1165/rcmb.2002-0071OC.CrossRefPubMedGoogle Scholar
  28. 28.
    Even-Or E, Ghandourah H, Ali M, Krueger J, Sweezey NB, Schechter T. Efficacy of high-dose steroids for bronchiolitis obliterans syndrome post pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2018;22(2).  https://doi.org/10.1111/petr.13155.
  29. 29.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.  https://doi.org/10.1016/j.bbmt.2005.09.004.CrossRefPubMedGoogle Scholar
  30. 30.
    Fowler KA, Jania CM, Tilley SL, Panoskaltsis-Mortari A, Baldwin AS, Serody JS, Coghill JM. Targeting the canonical nuclear factor-kappaB pathway with a high-potency IKK2 inhibitor improves outcomes in a mouse model of idiopathic pneumonia syndrome. Biol Blood Marrow Transplant. 2017;23(4):569–80.  https://doi.org/10.1016/j.bbmt.2017.01.083.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant. 2001;7(1):49–57.  https://doi.org/10.1053/bbmt.2001.v7.pm11215699.CrossRefPubMedGoogle Scholar
  32. 32.
    Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003;102(10):3822–8.  https://doi.org/10.1182/blood-2002-06-1813.CrossRefPubMedGoogle Scholar
  33. 33.
    Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, Maloney DG, Deeg HJ, Martin PJ, Storb RF, Madtes DK. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003;102(8):2777–85.  https://doi.org/10.1182/blood-2003-05-1597.CrossRefPubMedGoogle Scholar
  34. 34.
    Gulbahce HE, Manivel JC, Jessurun J. Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow transplantation. Am J Surg Pathol. 2000;24(8):1147–52.CrossRefGoogle Scholar
  35. 35.
    Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation. 1989;47(6): 989–92.CrossRefGoogle Scholar
  36. 36.
    Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–87.  https://doi.org/10.1164/ajrccm.159.1.9712108.CrossRefPubMedGoogle Scholar
  37. 37.
    Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM. Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant. 2018.  https://doi.org/10.1016/j.bbmt.2018.04.012.
  38. 38.
    Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke KR. Blockade of CXCR3 receptor: ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol. 2004;173(3):2050–9.CrossRefGoogle Scholar
  39. 39.
    Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler E. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1):67–74.  https://doi.org/10.1016/j.bbmt.2007.09.009.CrossRefPubMedGoogle Scholar
  40. 40.
    Holm AM, Riise GC, Hansson L, Brinch L, Bjortuft O, Iversen M, Simonsen S, Floisand Y. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant. 2013;48(5):703–7.  https://doi.org/10.1038/bmt.2012.197.CrossRefPubMedGoogle Scholar
  41. 41.
    Hosokawa K, Yamazaki H, Nishitsuji M, Kobayashi S, Takami A, Fujimura M, Nakao S. Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia. Intern Med. 2012;51(2):195–8.CrossRefGoogle Scholar
  42. 42.
    Ishii T, Manabe A, Ebihara Y, Ueda T, Yoshino H, Mitsui T, Hisakawa H, Yagasaki H, Kikuchi A, Yoshimasu T, Tanaka R, Takahashi T, Masunaga A, Sugita KI, Nakahata T, Asano S, Tsuji K. Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin. Bone Marrow Transplant. 2000;26(8): 907–10.  https://doi.org/10.1038/sj.bmt.1702642.CrossRefPubMedGoogle Scholar
  43. 43.
    Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e381.  https://doi.org/10.1016/j.bbmt.2014.12.001.CrossRefGoogle Scholar
  44. 44.
    Jo KW, Yoon S, Song JW, Shim TS, Lee SW, Lee JS, Kim DY, Lee JH, Lee JH, Choi Y, Lee KH. The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Int J Hematol. 2015;102(3):357–63.  https://doi.org/10.1007/s12185-015-1830-0.CrossRefPubMedGoogle Scholar
  45. 45.
    Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997;63(8):1079–86.CrossRefGoogle Scholar
  46. 46.
    Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95(11):1935–42.  https://doi.org/10.3324/haematol.2010.026104.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Koinuma T, Nunomiya S, Wada M, Koyama K, Suzuki T. Concurrent treatment with a tumor necrosis factor-alpha inhibitor and veno-venous extracorporeal membrane oxygenation in a post-hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome: a case report. J Intensive Care. 2014;2(1):48.  https://doi.org/10.1186/s40560-014-0048-1.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, Leung AY, Kwong YL, Liang RH, Lam WK, Ip MS, Lie AK. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT–a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011;46(12):1551–6.  https://doi.org/10.1038/bmt.2011.1.CrossRefPubMedGoogle Scholar
  49. 49.
    Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.  https://doi.org/10.1182/blood-2008-09-178046.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Lee KS, Kullnig P, Hartman TE, Muller NL. Cryptogenic organizing pneumonia: CT findings in 43 patients. AJR Am J Roentgenol. 1994;162(3): 543–6.  https://doi.org/10.2214/ajr.162.3.8109493.CrossRefPubMedGoogle Scholar
  51. 51.
    Liao WI, Tsai SH, Chiu SK. Successful use of extracorporeal membrane oxygenation in a hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome. Respir Care. 2013;58(2):e6–10.  https://doi.org/10.4187/respcare.01716.CrossRefPubMedGoogle Scholar
  52. 52.
    Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, Vaughan LA, Kassim A, Schuening F, Jagasia M. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011;46(3):426–9.  https://doi.org/10.1038/bmt.2010.152.CrossRefPubMedGoogle Scholar
  53. 53.
    Majeski EI, Paintlia MK, Lopez AD, Harley RA, London SD, London L. Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes. Am J Pathol. 2003;163(4): 1467–79.  https://doi.org/10.1016/S0002-9440(10)63504-3.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2000;162(5):1964–73.  https://doi.org/10.1164/ajrccm.162.5.9912045.CrossRefPubMedGoogle Scholar
  55. 55.
    Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, Tomassetti S, Piciucchi S, Poletti V, Zompatori M. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. Diagn Interv Radiol. 2016;22(5):400–6.  https://doi.org/10.5152/dir.2016.15516.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest. 2002;109(6):707–12.  https://doi.org/10.1172/JCI15293.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, Kurokawa M, Takahashi S, Ooi J, Shimizu T, Yokota A, Yoshiba F, Fujimaki K, Kanamori H, Sakai R, Saitoh T, Sakura T, Maruta A, Sakamaki H, Okamoto S. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93(3): 375–82.  https://doi.org/10.1007/s12185-011-0809-8.CrossRefPubMedGoogle Scholar
  58. 58.
    Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, Ogawa H, Miyamura K, Eto T, Sakamaki H, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(10):1317–23.  https://doi.org/10.1038/bmt.2013.116.CrossRefPubMedGoogle Scholar
  59. 59.
    Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3): 709–18.  https://doi.org/10.1182/blood-2009-02-204156.CrossRefPubMedGoogle Scholar
  60. 60.
    Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, Cooke KR, American Thoracic Society Committee on Idiopathic Pneumonia Syndrome. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183(9):1262–79.  https://doi.org/10.1164/rccm.2007-413ST.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Paz HL, Crilley P, Patchefsky A, Schiffman RL, Brodsky I. Bronchiolitis obliterans after autologous bone marrow transplantation. Chest. 1992;101(3): 775–8.CrossRefGoogle Scholar
  62. 62.
    Pena E, Souza CA, Escuissato DL, Gomes MM, Allan D, Tay J, Dennie CJ. Noninfectious pulmonary complications after hematopoietic stem cell transplantation: practical approach to imaging diagnosis. Radiographics. 2014;34(3):663–83.  https://doi.org/10.1148/rg.343135080.CrossRefPubMedGoogle Scholar
  63. 63.
    Pipavath SN, Chung JH, Chien JW, Godwin JD. Organizing pneumonia in recipients of hematopoietic stem cell transplantation: CT features in 16 patients. J Comput Assist Tomogr. 2012;36(4):431–6.  https://doi.org/10.1097/RCT.0b013e31825ba274.CrossRefPubMedGoogle Scholar
  64. 64.
    Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J. 1996;9(12):2513–6.CrossRefGoogle Scholar
  65. 65.
    Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant. 2005;36(2):135–8.  https://doi.org/10.1038/sj.bmt.1705026.CrossRefPubMedGoogle Scholar
  66. 66.
    Sakaguchi H, Takahashi Y, Watanabe N, Doisaki S, Muramatsu H, Hama A, Shimada A, Yagasaki H, Kudo K, Kojima S. Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2012;58(5):780–4.  https://doi.org/10.1002/pbc.23298.CrossRefPubMedGoogle Scholar
  67. 67.
    Sakai R, Kanamori H, Nakaseko C, Yoshiba F, Fujimaki K, Sakura T, Fujisawa S, Kawai N, Onoda M, Matsushima T, Maruta A, Sakamaki H, Okamoto S. Air-leak syndrome following allo-SCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant. 2011;46(3):379–84.  https://doi.org/10.1038/bmt.2010.129.CrossRefPubMedGoogle Scholar
  68. 68.
    Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys. 2005;63(3):876–84.  https://doi.org/10.1016/j.ijrobp.2005.02.032.CrossRefPubMedGoogle Scholar
  69. 69.
    Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, Horowitz MM. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128(1):153–61.  https://doi.org/10.1378/chest.128.1.153.CrossRefPubMedGoogle Scholar
  70. 70.
    Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol. 2005;60(1):47–55.  https://doi.org/10.1016/j.crad.2004.08.016.CrossRefPubMedGoogle Scholar
  71. 71.
    Schlatzer DM, Dazard JE, Ewing RM, Ilchenko S, Tomcheko SE, Eid S, Ho V, Yanik G, Chance MR, Cooke KR. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Mol Cell Proteomics. 2012;11(6):M111 015479.  https://doi.org/10.1074/mcp.M111.015479.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Seo S, Renaud C, Kuypers JM, Chiu CY, Huang ML, Samayoa E, Xie H, Yu G, Fisher CE, Gooley TA, Miller S, Hackman RC, Myerson D, Sedlak RH, Kim YJ, Fukuda T, Fredricks DN, Madtes DK, Jerome KR, Boeckh M. Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. Blood. 2015;125(24):3789–97.  https://doi.org/10.1182/blood-2014-12-617035.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Shankar G, Scott Bryson J, Darrell Jennings C, Kaplan AM, Cohen DA. Idiopathic pneumonia syndrome after allogeneic bone marrow transplantation in mice. Role of pretransplant radiation conditioning. Am J Respir Cell Mol Biol. 1999;20(6):1116–24.  https://doi.org/10.1165/ajrcmb.20.6.3455.CrossRefPubMedGoogle Scholar
  74. 74.
    Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010;3(3):143–57.CrossRefGoogle Scholar
  75. 75.
    Spira D, Faul C, Schaup V, Wirths S, Schulze M, Sauter A, Horger M. HRCT findings in idiopathic pneumonia syndrome with documentation of the disease course. Eur J Radiol. 2012;81(2):e147–52.  https://doi.org/10.1016/j.ejrad.2011.01.055.CrossRefPubMedGoogle Scholar
  76. 76.
    Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570–80.  https://doi.org/10.1182/blood-2011-07-364414.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P, Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation, the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer, the International Immunocompromised Host Society and the European Leukemia Net. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7): 803–11.  https://doi.org/10.3324/haematol.2016.144428.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Thirman MJ, Devine SM, O’Toole K, Cizek G, Jessurun J, Hertz M, Geller RB. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992;10(3):307–11.PubMedGoogle Scholar
  79. 79.
    Thompson J, Yin Z, D’Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and corticosteroid therapy for the treatment of late-onset idiopathic pneumonia syndrome. Biol Blood Marrow Transplant. 2017;23(11):1955–60.  https://doi.org/10.1016/j.bbmt.2017.07.019.CrossRefPubMedGoogle Scholar
  80. 80.
    Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 2012;47(10):1332–7.  https://doi.org/10.1038/bmt.2011.260.CrossRefPubMedGoogle Scholar
  81. 81.
    Ueda K, Watadani T, Maeda E, Ota S, Kataoka K, Seo S, Kumano K, Hangaishi A, Takahashi T, Imai Y, Ohtomo K, Fukayama M, Nannya Y, Kurokawa M. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1719–27.  https://doi.org/10.1038/bmt.2010.48.CrossRefPubMedGoogle Scholar
  82. 82.
    Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Muller KG. Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant. 2012;47(8):1020–9.  https://doi.org/10.1038/bmt.2011.161.CrossRefPubMedGoogle Scholar
  83. 83.
    Vande Vusse LK, Madtes DK. Early onset noninfectious pulmonary syndromes after hematopoietic cell transplantation. Clin Chest Med. 2017;38(2): 233–48.  https://doi.org/10.1016/j.ccm.2016.12.007.CrossRefPubMedGoogle Scholar
  84. 84.
    Vande Vusse LK, Madtes DK, Guthrie KA, Gernsheimer TB, Curtis JR, Watkins TR. The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation. Transfusion. 2014;54(4):1071–80.  https://doi.org/10.1111/trf.12396.CrossRefPubMedGoogle Scholar
  85. 85.
    Vande Vusse LK, Madtes DK, Bolgiano D, Watkins TR. The association between platelet transfusion and idiopathic pneumonia syndrome is unaffected by platelet product type. Transfusion. 2016;56(2): 489–96.  https://doi.org/10.1111/trf.13361.CrossRefPubMedGoogle Scholar
  86. 86.
    Vogl UM, Nagayama K, Bojic M, Hoda MA, Klepetko W, Jaksch P, Dekan S, Siersch V, Mitterbauer M, Schellongowski P, Greinix HT, Petkov V, Schulenburg A, Kalhs P, Rabitsch W. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation. 2013;95(4):623–8.  https://doi.org/10.1097/TP.0b013e318277e29e.CrossRefPubMedGoogle Scholar
  87. 87.
    von der Thusen JH, Hansell DM, Tominaga M, Veys PA, Ashworth MT, Owens CM, Nicholson AG. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011;24(12):1633–9.  https://doi.org/10.1038/modpathol.2011.114.CrossRefPubMedGoogle Scholar
  88. 88.
    Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011;37(1):164–72.  https://doi.org/10.1183/09031936.00068310.CrossRefGoogle Scholar
  89. 89.
    Watanabe K. Pleuroparenchymal fibroelastosis: its clinical characteristics. Curr Respir Med Rev. 2013;9:299–37.  https://doi.org/10.2174/1573398X0904140129125307.CrossRefPubMedGoogle Scholar
  90. 90.
    Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HE, Kolb HJ, Hartz AJ, Rimm AA. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med. 1986;104(2):168–75.CrossRefGoogle Scholar
  91. 91.
    Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448–55.  https://doi.org/10.1182/blood-2016-08-693507.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–6.  https://doi.org/10.1016/j.bbmt.2015.10.009.CrossRefGoogle Scholar
  93. 93.
    Woodard JP, Gulbahce E, Shreve M, Steiner M, Peters C, Hite S, Ramsay NK, DeFor T, Baker KS. Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transplant. 2000;25(3):293–300.  https://doi.org/10.1038/sj.bmt.1702137.CrossRefPubMedGoogle Scholar
  94. 94.
    Yang S, Milla C, Panoskaltsis-Mortari A, Ingbar DH, Blazar BR, Haddad IY. Human surfactant protein a suppresses T cell-dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. Am J Respir Cell Mol Biol. 2001;24(5):527–36.  https://doi.org/10.1165/ajrcmb.24.5.4400.CrossRefPubMedGoogle Scholar
  95. 95.
    Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(7):1044–54.  https://doi.org/10.1016/j.bbmt.2011.11.031.CrossRefPubMedGoogle Scholar
  96. 96.
    Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014;20(6):858–64.  https://doi.org/10.1016/j.bbmt.2014.02.026.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schultz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015;21(1):67–73.  https://doi.org/10.1016/j.bbmt.2014.09.019.CrossRefPubMedGoogle Scholar
  98. 98.
    Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7): 749–59.  https://doi.org/10.1016/j.bbmt.2007.05.001.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Kevin Dsouza
    • 1
  • Cameron Pywell
    • 2
  • Victor J. Thannickal
    • 1
    Email author
  1. 1.Division of Pulmonary, Allergy and Critical Care Medicine, Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA

Section editors and affiliations

  • Yenny Cardenas
    • 1
  1. 1.Critical Care DepartmentUniversidad del Rosario Hospital Universitario Fundacion Santa Fe deBogotaColombia

Personalised recommendations